Law FirmOpposition Filing Analysis

The comprehensive analysis of Sonnenhauser opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Sonnenhauser

Patent NumberTitleApplicantOpposition DateOpposition Company
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025WUESTHOFF & WUESTHOFF
Pharmaceutical Composition For The Treatment Of Pulmonary Arterial HypertensionACTELION PHARMACEUTICALSFeb 21, 2025SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Xylylene Diisocyanate Composition, Modified Xylylene Diisocyanate Composition, Polymerizable Composition, Resin, Molded Body, Optical Element, And LensMITSUI CHEMICALSFeb 12, 2025WUESTHOFF & WUESTHOFF
New UseNOVARTISJul 10, 2024WUESTHOFF & WUESTHOFF
Medical Use Of A Dpp-4 InhibitorBOEHRINGER INGELHEIMMar 26, 2024WUESTHOFF & WUESTHOFF
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol HydrateASTRAZENECAFeb 6, 2024WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB
Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) InhibitorNOVARTISAug 16, 2023WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISMay 10, 2023WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB
Direct Compression Formulation And ProcessNOVARTISMay 30, 2022WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB
Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or RemodelingNOVARTISJan 27, 2022WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB